Resource: FDA Issues Emergency Use Authorization for Third COVID-19 Vaccine
Source: U.S. Food and Drug Administration
Synopsis: The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the third vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The EUA allows the Janssen COVID-19 Vaccine to be distributed in the U.S for use in individuals 18 years of age and older.
Comment: This is the widely anticipated vaccine from Johnson & Johnson. This is a single dose vaccine which has 66% effectiveness against moderate to severe COVID-19. The CDC expects the 3.9 million Janssen doses will likely be divided as follows: 2.8 million doses for states, 800,000 doses for retail pharmacies, 70,000 doses for community vaccine centers, and 90,000 doses for federally qualified health centers.
